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Abstract
Background: Recent findings from microarray studies have raised the prospect of a standardized
diagnostic gene expression platform to enhance accurate diagnosis and risk stratification in
paediatric acute lymphoblastic leukaemia (ALL). However, the robustness as well as the format for
such a diagnostic test remains to be determined. As a step towards clinical application of these
findings, we have systematically analyzed a published ALL microarray data set using Robust Multi-
array Analysis (RMA) and Random Forest (RF).
Methods:  We examined published microarray data from 104 ALL patients specimens, that
represent six different subgroups defined by cytogenetic features and immunophenotypes. Using
the decision-tree based supervised learning algorithm Random Forest (RF), we determined a small
set of genes for optimal subgroup distinction and subsequently validated their predictive power in
an independent patient cohort.
Results: We achieved very high overall ALL subgroup prediction accuracies of about 98%, and
were able to verify the robustness of these genes in an independent panel of 68 specimens obtained
from a different institution and processed in a different laboratory. Our study established that the
selection of discriminating genes is strongly dependent on the analysis method. This may have
profound implications for clinical use, particularly when the classifier is reduced to a small set of
genes. We have demonstrated that as few as 26 genes yield accurate class prediction and
importantly, almost 70% of these genes have not been previously identified as essential for class
distinction of the six ALL subgroups.
Conclusion:  Our finding supports the feasibility of qRT-PCR technology for standardized
diagnostic testing in paediatric ALL and should, in conjunction with conventional cytogenetics lead
to a more accurate classification of the disease. In addition, we have demonstrated that microarray
findings from one study can be confirmed in an independent study, using an entirely independent
patient cohort and with microarray experiments being performed by a different research team.
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Background
Acute lymphoblastic leukaemia (ALL) is a heterogeneous
disease characterized by the presence of several subtypes
that are of prognostic relevance. These subtypes can be
distinguished based on immunophenotype, differentia-
tion status, as well as chromosomal and molecular abnor-
malities. The identification of different ALL subtypes, the
characterization of prognostic features, and the finding
that ALL subtypes differ in their response to therapy has
greatly facilitated the development of treatments tailored
to specific subgroups [1-3]. Current National Cancer Insti-
tute (NCI) criteria for risk assignment utilise age and
white blood cell counts (WBC) at diagnosis to stratify
patients into standard risk (SR; 1-9.99 years of age and
WBC<50,000/μl) and high risk (HR; ≥ 10 years of age or
WBC ≥ 50,000/μl) [4]. In addition, several structural and
numerical chromosomal abnormalities are known as
independent prognostic factors. For example, the t(9;22)
translocation is strongly associated with poor prognosis,
whilst both t(12;21) translocations and high hyperdip-
loid karyotypes (>50 chromosomes) confer a favourable
prognosis [5-7]. Although detection accuracies for chro-
mosomal abnormalities can be as high as 90%, the suc-
cess rate varies greatly and cytogenetic analysis remains a
challenge due to the low mitotic index and poor quality of
the metaphases associated with ALL [7,8]. Cytogenetic
interpretation can be particularly difficult for complex
karyotypes, cryptic translocations such as the TEL-AML1
translocation, and multiple chromosomal rearrange-
ments that have been identified for the same locus, as is
the case for chromosomal abnormalities involving the
MLL gene. Thus, multiple complementary technologies,
such as fluorescence in situ hybridization (FISH), spectral
karyotyping (SKY), Southern blot analysis and RT-PCR,
are often required for the accurate identification of chro-
mosomal abnormalities and hence add to the extremely
time-consuming and expensive process of cytogenetic
analysis [5-7,9].
Recent advances in microarray technology have shown
that subgroups of ALL as well as acute myeloid leukaemia
(AML) can be accurately distinguished based on their gene
expression profiles [10-16]. Two of the largest childhood
ALL microarray studies published so far demonstrated the
presence of distinct gene expression patterns in six known
prognostic subgroups [13,14]. Using supervised learning
algorithms to assign ALL samples into their respective
subgroups, the study conducted at the St. Jude Children's
Research Hospital achieved an overall prediction accuracy
of about 96% [14]. The findings from this and other stud-
ies raised the prospect of developing a standardized diag-
nostic gene expression platform to enhance accurate
diagnosis and risk stratification. One of the major chal-
lenges that lies ahead is how the information gained
through microarray experiments can be applied to clinical
diagnostics, including the issue of whether to employ
microarrays themselves as a platform for testing. Here, we
explored the possibility of using a small number of genes
in such a test, which would allow the exploitation of
quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) as an alternative method for diagnostic
screening. Compared to microarray technology, qRT-PCR
has the advantage of being less expensive, rapid, already
established in many laboratories and independent of
extensive computational analysis. We examined the ALL
microarray data set published by Ross et al [14], focusing
on 104 specimens from ALL patients that represent six dif-
ferent subgroups defined by cytogenetic features and
immunophenotypes. Using the decision-tree based super-
vised learning algorithm Random Forest (RF), we deter-
mined a small set of genes for optimal subgroup
distinction and subsequently validated their predictive
power in an independent patient cohort. We showed that
only 26 genes are required to accurately discriminate the
six known prognostic subgroups of paediatric ALL, a
number small enough to allow their expression levels to
be measured by modern qRT-PCR technology in a clinical
setting.
Methods
Patient specimens and gene expression profiling
The study material included 47 Ficoll-Hypaque purified
and cryopreserved bone marrow (BM) or peripheral
blood (PB) specimens from children diagnosed with ALL
at Princess Margaret Hospital for Children, Perth, Western
Australia and 21 ALL cell lines [17]. A few cell lines
included in the study are available from tissue banks,
however the majority were derived from paediatric ALL
patients treated at the same hospital. The study was
approved by the Institutional Review Board and informed
consent for the use of tissues for research purposes was
obtained for all patients involved in this study. Standard
cytogenetic and immunofluorescence analysis was per-
formed on pre-treatment bone marrow, peripheral blood
specimens and established cell lines. The average blast
percentage for the specimens was 89.2% ± 11.0. Total
RNA was extracted as described previously [18]. Bioti-
nylated cRNA was prepared from 2 μg of total RNA,
hybridized to Affymetrix HG-U133A oligonucleotide
microarrays (Affymetrix, Santa Clara, CA) and arrays were
subsequently washed, stained and scanned using a Gene-
Array Scanner (Agilent Technologies, Palo Alto, CA)
according to Affymetrix protocols.
Data extraction and normalization
Array images were reduced to intensity values for each
probe (cel files) using Affymetrix MAS 5.0 software. These
cel files were analyzed using the statistical software R 1.7.1
[19, 46]. The software, Methods for Affymetrix Oligonu-
cleotide Arrays [20], a suite of functions for R, is availableBMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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from the Bioconductor website [47]. Expression measures
were extracted using robust multi-array analysis (RMA)
[21] as previously described [22]. HG-U133A and HG-
U133B raw data (cel files) from the ALL data set published
by Ross and colleagues [14, 48] were processed as
described above.
Statistical analysis
Prior to analysis of the data set obtained by Ross et al [14],
samples not belonging to either of the six ALL subgroups
(Others n = 28) were removed. The remaining samples (n
= 104) were used to identify subgroup-discriminating
probe sets according to the parallel approach described by
Ross et al [14], defined as the comparison of cases in one
subgroup versus all other cases. First, we applied a vari-
ance filter to eliminate non-informative probe sets. We
excluded all probe sets from the analysis with a fold-
change <1.15 between patient subgroups and a p-value
associated with this fold-change of >0.1, calculated using
a permutation test (999 permutations).
Supervised analysis was then performed separately for
HG-U133A and HG-U133B data and each of the sub-
groups with the remaining, informative probe sets using
the decision-tree based algorithm Random Forest (RF,
randomForest 3.4 standard settings) [23]. In brief, each RF
analysis consisted of 100,000 trees and for each tree, the
intrinsic RF reiterative process randomly chooses a subset
of samples and probe sets for initial analysis and subse-
quently uses the remaining samples for testing back.
Finally, all probe sets used for RF analysis are ranked
according to their ability to discriminate between the
groups of interest and for each sample a classification
accuracy is obtained, along with a measure of confidence
[24].
For the six subgroups (T-ALL, hyperdiploid >50, E2A-
PBX1,  MLL,  BCR-ABL,  TEL-AML1) 5707, 4284, 4490,
3815, 2385, 3660 HG-U133A probe sets and 1320, 3035,
1379, 1212, 976, 1347 HG-U133B probe sets passed the
variance filter. The 1000 top-ranked probe sets for each
subgroup from this initial separate analysis of HG-U133A
and HG-U133B were combined (a total of 2000 discrimi-
nating probe sets per subgroup) and subjected to a second
RF analysis. Subsequently, the 20 highest-ranked sub-
group-discriminating probe sets were combined and
assessed for their predictive performance using RF. The
entire analysis was performed again, using MAS 5.0-calcu-
lated expression values as published by Ross et al [14]
instead of data generated by RMA.
For cross validation, the samples were randomly divided
into a training set (n = 79) and a test set (total n = 25, BCR-
ABL n = 4, E2A-PBX1 n = 5, Hyperdiploid>50 n = 4, MLL
n = 5, T-ALL n = 2, TEL-AML1 n = 5) and the analysis pro-
cedure described above, including the application of a
variance filter, was performed 100 times [25,26]. For each
analysis a new training and test set was chosen and dis-
criminating probe sets were selected using the new train-
ing set.
PCA was used to visualize different discriminant analyses.
In order to compare PCA scatter plots we determined a
measure for the spatial separation of clusters, which
describes tightness of clustering within each subgroup, as
well as between subgroups. For this measure we first cal-
culated the sum of the squared distances from each data
point to the overall centre of the data (Sum Squared Total)
and then the sum of the squared distances from each data
point within one subgroup to the centre of its appropriate
cluster (Sum Squared Within cluster). The spatial cluster
separation was expressed as 1 – SSW/SST.
Additional files
Supplementary information on the specimens and results
from the statistical analyses are available as additional
files. The primary data are available from ArrayExpress
under the accession number E-TABM-125 according to
MIAME guidelines [49].
Results
Confirmation of discrimination between prognostic ALL 
subtypes
A study published by Ross and colleagues [14] reported
the discrimination of six prognostic ALL subgroups based
on 120 probe sets, using artificial neural network (ANN)
as supervised learning algorithm. Comparable results
were also reported when the authors used other super-
vised learning algorithms for classification, such as sup-
port vector machine (SVM) and k-nearest neighbours (k-
NN). We opted to use a different method for analysis,
comprising of RMA as data extraction method and the
supervised learning algorithm RF to identify subgroup-
discriminating probe sets (RMA/RF). Mirroring the analy-
sis strategy applied by Ross et al [14], we compared all
samples within one subgroup against all other samples
(termed "parallel approach" by the authors), and identi-
fied the top 20 discriminating probe sets for each of the six
subgroups (see Materials and Methods for a more detailed
description of the analysis). The number of samples rep-
resenting each of the six subgroups ranged from 14–20
(Table 1). RF classification with these top-ranked 120 dis-
criminating probe sets (20 probe sets for each of the sub-
groups) achieved accurate discrimination of all
subgroups, with the exception of two apparent misclassi-
fications in the BCR-ABL subgroup (Table 1). However,
these two cases are known to exhibit a BCR-ABL transloca-
tion as well as a hyperdiploid karyotype [14]. Overall, RF
analysis achieved a slightly higher prediction accuracy of
98.1% compared to 96.4% obtained using ANN [14]. TheBMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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discrimination of the six ALL subtypes based on 120
probe sets is further illustrated in Figure 1A using PCA.
Comparison of prediction accuracies
To be able to directly compare the prediction accuracies
accomplished using RF versus ANN, we implemented the
cross validation procedure described by Ross et al [14] and
divided the samples into a training set (n = 79) and a test
set (n = 25, see Materials and Methods for details and
Table 1). After the implementation of this cross valida-
tion, the overall prediction accuracy achieved by RF was
98.2% compared to 96.4% obtained using ANN (Table
1). As in the previous RF analysis, the classification accu-
racy was virtually 100% for five of the subgroups. The
only apparent misclassifications occurred in the BCR-ABL
subgroup due to the same two samples showing the BCR-
ABL translocation and a hyperdiploid karyotype. In con-
trast, the cross validation performed by Ross et al [14]
using ANN resulted in additional misclassifications of
samples from the hyperdiploid and the TEL-AML1 sub-
group, with prediction accuracies of 95% and 96%,
respectively. Importantly, comparable prediction accura-
cies of 98.1% and 98.2% were obtained with the initial RF
analysis and the cross validation RF analysis, indicating
that RF is less prone to over fitting the data, which is a
common problem associated with most other supervised
learning algorithms. These results therefore verified our
analysis approach and validated RF as a suitable alterna-
tive supervised learning algorithm for the analysis of oli-
gonucleotide array data.
RMA/RF analysis identifies novel discriminator genes for 
ALL subgroups
An important step in the analysis of microarray data is the
selection of a set of discriminators that achieve optimal
classification. To assess whether different analysis
approaches would generate different lists of discriminat-
ing genes, we compared the top 120 discriminators for the
six ALL subgroups identified by RF in the present study to
those identified by Ross et al [14] who used a chi-square
metric. Surprisingly, only 35–65% of probe sets were
commonly identified in the two analyses (see Additional
files 1, 2, 5). The highest level of concurrence was
observed for the T-ALL,E2A-PBX1  and  TEL-AML1  sub-
groups, with 65% of probe sets identified by both analy-
ses. In contrast, most discrepancies were found for the
hyperdiploid subgroup, with only 35% of probe sets iden-
tified in both analyses. Since some genes are represented
by multiple probe sets, we subsequently compared the
number of genes that had been determined to be sub-
group discriminators. As expected, similar findings were
obtained; 35–71.4% of genes were commonly identified
in both analyses, although a higher level of agreement was
observed for some subgroups (see Additional files 1, 2, 5).
Interestingly, we generally observed lower average fold-
changes and expression levels for discriminating genes
selected by RF, compared to the analysis performed by
Ross et al [14] (see Additional file 1). The lowest fold-
changes in expression levels were detected for genes defin-
ing the hyperdiploid subgroup, a finding that agrees with
the observations made by Ross et al [14].
We hypothesized that the relatively low representation of
common genes in both analyses might be due to either
the different approaches used for data extraction (RMA
versus MAS 5.0), the methods used for feature selection
(RF versus chi-square), or a combination of both. To
address this issue, we repeated the entire analysis with the
expression values generated by MAS 5.0 as published by
Ross et al [14]. This analysis identified a third set of dis-
criminators which captured around 65% of the probe sets
identified by either RMA/RF analysis or the analysis per-
Table 1: Comparison of prediction accuracies achieved by RMA/RF and ANN (Ross et al., 2003).
RMA/RF RMA/RF‡ Ross et al.†
Analysis method RF RF ANN
Samples in test set 104 25 25
BCR-ABL accuracy (samples) 86.7 % (15)* 89 % (4)* 87.5 % (4)*
E2A-PBX1 accuracy (samples) 100 % (18) 100 % (5) 100 % (5)
Hyperdip>50 accuracy (samples) 100 % (17) 99.8 % (4) 95 % (4)
MLL accuracy (samples) 100 % (20) 100 % (5) 100 % (5)
T-ALL accuracy (samples) 100 % (14) 100 % (2) 100 % (2)
TEL-AML1 accuracy (samples) 100 % (20) 100 % (5) 96 % (5)
Overall accuracy 98.1 % 98.2 % 96.4 %
*By cytogenetic analysis both cases that led to apparent inaccuracies are known to show the presence of BCR-ABL and >50 chromosomes.
‡ Average prediction accuracies from 100 independent analyses. For each analysis a new training and test set was chosen and discriminating probe 
sets were selected using the new training set.
† Average prediction accuracies from 10 independent analyses. For each analysis a new training and test set was chosen and discriminating probe 
sets were selected using the new training set.BMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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formed by Ross et al [14] (data not shown). These results
clearly demonstrate that different approaches used for
data extraction and selection of discriminating genes can
lead to the identification of different sets of class discrim-
inating genes.
Accurate classification of ALL subtypes using 26 genes
The reduction of discriminators to a small set of genes is a
prerequisite for a diagnostic test that could easily be per-
formed in a clinical setting. We addressed this issue firstly
by assessing whether the number of subgroup discrimi-
nating genes could be reduced. Secondly, we determined
whether reduced numbers of discriminator genes would
still yield accurate class assignment in a cross validation
procedure (see Materials and Methods for details). This
analysis was performed with a total of 90, 60, 30 and 12
probe sets (the top 15, top 10, top 5 and top 2 probe sets
per subgroup, respectively). The results of this analysis are
summarized in Figure 2 (see Additional file 3) and
showed that accurate discrimination of the six ALL sub-
groups can indeed be achieved with a reduced number of
probe sets. Comparable average prediction accuracies of
98.1%, 98.1% and 98% were obtained with 90, 60 and 30
probe sets, while the reduction to 12 probe sets resulted in
a slightly lower average prediction accuracy of 97.4% (Fig-
ure 2). Importantly, the levels of accuracy were very simi-
lar to the prediction accuracy achieved using 120 probe
sets, and included the apparent misclassification of the
two samples known to exhibit a BCR-ABL translocation
and a hyperdiploid karyotype. Using either 90, 60 or 30
probe sets, additional misclassification occurred with very
low frequencies (3.2–11.5%) for two individual speci-
mens with a hyperdiploid karyotype and one BCR-ABL-
expressing ALL. The reduction to only 12 probe sets
resulted in further misclassification of cases belonging to
all subgroups, again with low frequencies of 3.4–20.8%
for individual specimens (Figure 2 and see Additional file
3). Therefore, 30 probe sets representing the top 5 probe
sets for each of the six subgroups and a total of 26 genes
can be used for accurate discrimination of six prognostic
ALL subgroups (Table 2), which is further illustrated by a
PCA scatter plot shown in Figure 1B. Importantly, we
observed no differences in PCAs using either 120 or 30
probe sets, since the same degree of spatial cluster separa-
tion (see Materials and methods for details) was found in
both analyses.
Discriminators identified by RMA/RF accurately predict 
prognostic ALL subtypes in an independent data set
A fundamental requirement for the development of diag-
nostic tests is that the genes identified as discriminators in
a particular study can be shown to be generally applicable.
Thus, we determined whether the discriminator genes
identified in the present study using RMA/RF were able to
distinguish between the prognostic subgroups in our own
cohort of 47 ALL patient specimens and 21 cell lines, rep-
resenting the six ALL subgroups (Table 3 and see Addi-
tional file 4). We assessed the gene expression profiles for
this independent cohort using Affymetrix HG-U133A
microarrays. For this reason the entire analysis of the data
set published by Ross and colleagues [14] described above
was repeated, this time however using the HG-U133A
data only. The resulting 120 probe sets were then applied
to a RF analysis and the RF trained on the Ross data set was
used for the classification of our 68 ALL specimens. This
analysis revealed that the majority of samples in our data
set were correctly classified into their respective sub-
groups, with an overall prediction accuracy of 92.6%
(Table 3). The misclassifications included 4 cases with a
hyperdiploid karyotype. Based on their gene expression
ALL subtype distinction based on discriminating genes identi- fied by RMA/RF Figure 1
ALL subtype distinction based on discriminating 
genes identified by RMA/RF. Gene expression profiles 
from 104 paediatric ALL specimens were analyzed using 
unsupervised Principle Component Analysis (PCA). Shown 
are three-dimensional scatter plots of all cases using PCA 
with the top discriminating probe sets identified by RMA/RF. 
(A) Three-dimensional scatter plot of a PCA using the top 20 
subgroup-discriminating probe sets (120 probe sets). (B) 
Three-dimensional scatter plot of a PCA using the top 5 sub-
group-discriminating probe sets (30 probe sets). Arrows 
mark two BCR-ABL-expressing samples known to contain a 
BCR-ABL translocation and a hyperdiploid (>50 chromo-
somes) karyotype.BMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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profiles these samples were classified as BCR-ABL-positive
in three cases and as MLL-positive in one case. In addition,
one T-ALL sample was wrongly classified as MLL leukae-
mia. Importantly, when we reduced the number of dis-
criminators to the top 30 probe sets, the RF trained on the
Ross data set again classified our 68 ALL specimens with
high accuracy (89.7%). This time, all samples of the T-
ALL, BCR-ABL, E2A-PBX1 and TEL-AML1 subgroups were
accurately classified, while misclassifications occurred
only for cases of the hyperdiploid and the MLL subgroup
(Table 3). The combined results clearly demonstrated that
the discriminator genes identified by RMA/RF are gener-
ally applicable and are able to distinguish six prognostic
subtypes of paediatric ALL in an independent data set.
Discussion
The objective of many microarray studies is the improve-
ment of diagnosis with the aim of accurately assigning
patients into specific risk categories that facilitate risk-
adapted therapy. Recent studies have demonstrated the
great potential of gene expression profiling for the classi-
fication of clinically relevant subtypes of paediatric leu-
kaemia [11-16]. The results from these studies are
promising and suggest that standardized gene expression-
based diagnostic tests can provide at least equivalent, if
not superior diagnostic accuracy compared to conven-
tional analysis methods. To critically assess whether find-
ings from gene expression profiling in paediatric ALL
could be adapted to diagnostic tests we have asked a set of
fundamental and very specific questions: 1) Can array
data be successfully applied to independent patient data,
i.e. are microarray findings robust and generally applica-
ble? 2) Is the selection of discriminating genes governed
by the approach chosen for the analysis of microarray data
and if so, is the selection of a different set of genes critical
for accurate class assignment? 3) Is it possible to drasti-
cally reduce the number of discriminating genes without
compromising the predictive performance? To answer
these questions we chose the leukaemia microarray data
set published by Ross et al [14] and re-analyzed the data
using RMA [20,21] for data extraction and normalization
and RF [23,27] as a supervised learning algorithm for the
selection of informative genes and class assignment.
To address the first question we used our RMA/RF analysis
approach to identify the top 20 discriminating probe sets
for each of the six ALL subgroups represented in this data
set. It is important to note that the patient cohort studied
by Ross and colleagues [14] was purposefully chosen to
represent all six subgroups in almost equal numbers. To
A small set of genes accurately predicts six ALL subgroups Figure 2
A small set of genes accurately predicts six ALL subgroups. Comparison of average prediction accuracies obtained 
with the top 20, top 15, top 10, top 5 and top 2 subgroup-discriminating probe sets identified by RMA/RF after cross validation 
(see Supplemental Document, Table S3). For each cross validation analysis (n = 100) a new training (n = 79) and test set (n = 
25) was chosen and discriminating probes sets were selected using the new training set. Shown are prediction accuracies for 
individual ALL subgroups (main panel) and the overall prediction accuracies (panel on the right).BMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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Table 3: Analysis of independent ALL patient cohort (n = 68). Confirmation of discriminators identified by RMA/RF using HG-U133A 
array data.
Subgroup* Number of specimens Correct classification Classification accuracy
Top 120 probe sets Top 30 probe sets Top 120 probe sets Top 30 probe sets
BCR-ABL 33 3 1 0 0 % 1 0 0 %
E2A-PBX1 33 3 1 0 0 % 1 0 0 %
Hyperdip>50 17 13 11 76.5% 64.7%
MLL 7 7 6 100% 85.7%
T-ALL 37 36 37 97.3% 100%
TEL-AML1 11 1 1 0 0 % 1 0 0 %
Total 68 63 61 92.6% 89.7%
* Established by conventional cytogenetic and immunophenotype analysis.
Table 2: Top 30 probe sets identified by RMA/RF that are required for accurate classification.
Subgroup Probe ID Gene Rank RMA/RF Rank Ross et al† Expression above/below mean Fold change
BCR-ABL 201906_s_at CTDSPL 1 17 Above 2.5
209365_s_at* ECM1 23 A b o v e 5 . 0
210830_s_at* PON2 32 A b o v e 5 . 7
202123_s_at ABL1 4 76 Above 2.0
222154_s_at DNAPTP6 5 13 Above 6.9
E2A-PBX1 212148_at* PBX1 14 A b o v e 2 9 . 6
221113_s_at WNT16 2 18 Above 6.2
205253_at* PBX1 33 A b o v e 3 6 . 1
230306_at• MGC10485 4 11 Above 5.9
225483_at• MGC10485 58 A b o v e 8 . 2
Hyperdipl.>50 200659_s_at PHB 1- A b o v e 2 . 8
216071_x_at* TNRC11 21 A b o v e 1 . 7
208598_s_at UREB1 3 12 Above 1.6
226875_at• DOCK11 4 35 Above 2.3
200057_s_at NONO 5- A b o v e 1 . 5
MLL 226939_at*• CPEB2 11 A b o v e 5
219463_at* C20orf103 22 A b o v e 1 5 . 2
204069_at* MEIS1 33 A b o v e 1 0
218847_at IMP-2 4 24 Above 7
201152_s_at MBNL1 5 23 Above 2.2
T-ALL 213539_at CD3D 1 17 Above 28.3
227646_at• EBF 22 3 B e l o w 2 4 . 6
217147_s_at TRIM 3 20 Above 10.1
229487_at• EBF 42 4 B e l o w 2 0 . 4
50221_at TFEB 5 - Below 2.2
TEL-AML1 206231_at KCNN1 1 15 Above 3.2
241505_at*• EST 2 4 Above 5.8
206033_s_at DSC3 3 12 Above 8.8
214110_s_at EST 4 - Above 2.2
206032_at DSC3 5 11 Above 4.8
† The ranking refers to the top 100 subgroup-discriminating probe sets identified by Ross et al. using the parallel analysis format.
* Probe sets/genes identified as the top 5 subgroup-discriminators in both analyses, RMA/RF and Ross et al. (parallel format).
• Probe sets that are represented on the HG-U133B array.BMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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independently test the discriminators identified by RMA/
RF in a less "idealized" cohort, we used our own microar-
ray data set, obtained by testing 68 paediatric ALL speci-
mens. This analysis validated the top subgroup-
discriminating genes identified by RMA/RF in an inde-
pendent cohort of ALL specimens achieving overall pre-
diction accuracies of up to 92.6%. Since our specimens
were assessed using HG-U133A arrays, several top-ranked
discriminators represented on the HG-U133B array were
not included and this may have accounted for a less pre-
cise classification of some samples. This is particularly
exemplified in case of the hyperdiploid subgroup where
one of the original top five discriminators is not present
on the HG-U133A array. Similarly, the only misclassifica-
tion of a case with MLL rearrangements might be due to
the highest-ranked discriminator not being part of the
HG-U133A array. Despite this, our findings clearly dem-
onstrate that the genes identified by RMA/RF as discrimi-
nators of the six ALL subgroups are robust and can be
applied to an independent cohort of patients. Impor-
tantly, this set of genes accurately classified samples from
an independent cohort that was obtained from a different
institution, in which subgroups were not artificially repre-
sented in equal numbers, and the performance was not
affected by laboratory-specific differences in terms of sam-
ple handling and data generation.
Unexpectedly, using our RMA/RF analysis we found a
high degree of discrepancy between genes identified as
most important discriminators for the six ALL subgroups
compared to those identified in the study published by
Ross et al [14]. Only 35–65% of probe sets and 35–71.4%
of genes were commonly identified in both analyses. This
finding highlights the existence of a large number of genes
with the potential to discriminate between subtypes of
paediatric ALL. Thus, the selection of discriminators, crit-
ical for achieving the most accurate classification and the
design of diagnostic tests, seems to be dependent on the
chosen analysis approach. While many microarray studies
report that similar classifications are obtained with differ-
ent supervised learning algorithms [13,14,28,29], so far
little attention has been paid to this critical aspect of
selecting discriminating genes [30-32]. Not surprisingly,
we found the highest degree of variability for discrimina-
tors identified for the cases with more than 50 chromo-
somes. Only 7 of the top 20 discriminating genes were
common between our analysis and the analysis con-
ducted by Ross et al [14]. These discrepancies coincide
with relatively low expression levels and particularly low
fold-changes observed for the genes defining this sub-
group, most likely reflecting the documented heterogene-
ity of this subgroup. Interestingly, the top-ranked gene
PHB has not previously been identified as an important
discriminator for this subgroup. Although the precise
function of PHB has yet to be clarified, it has been found
to play a role in several cellular processes, such as prolifer-
ation and apoptosis [33]. Other prominent subgroup-dis-
criminating genes identified by RMA/RF were ABL1 for the
BCR-ABL subgroup, and several B cell-specific genes with
very low expression levels in T-ALL samples, including the
transcription factor EBF, PAX5, a potential downstream
target of EBF [34], and the transcription factor TFEB. Fur-
thermore WNT16, a downstream target of the E2A-Pbx1
fusion protein [35], was found to be the second most
important discriminator for cases with E2A-PBX1  rear-
rangements. The results presented here highlight that the
selection of genes that distinguish best between ALL sub-
groups is strongly influenced by the methods used to ana-
lyze gene expression profiles, and this in turn may have
profound implications for clinical applications. While
RMA has more recently become a popular choice as data
extraction method [20,21], only few studies have reported
the use of RF as a supervised learning algorithm
[23,27,36]. RF is a decision tree-based algorithm and has
been proposed as particularly suitable for the high dimen-
sionality of microarray data sets. Comparisons with other
commonly used supervised learning algorithms have
shown that the RF algorithm constructs far more precise
classification rules [23]. Besides improved prediction
accuracies, a reduction in the number of genes required
for classification has also been reported when using deci-
sion tree-based methods [27].
Another critical issue that remains to be addressed is the
optimal platform for a diagnostic test to measure gene
expression profiles, i.e. low-density custom microarrays or
PCR-based assays. Many studies, including our own, have
shown that expression levels determined by microarray
can accurately be reproduced by qRT-PCR [13,22,37,38].
Compared to microarrays, qRT-PCR technology has the
advantage of being readily available in most laboratories,
being more cost-efficient and not involving extensive sta-
tistical and computational data analysis. However, a qRT-
PCR-based diagnostic platform would require the drastic
reduction in the number of genes measured. The compre-
hensive cross-validation procedures performed in this
study revealed that as few as 30 probe sets are sufficient to
achieve accurate class assignment. In contrast, a previous
study has reported that a single gene could identify T-ALL
and E2A-PBX1 cases, while 7–20 genes were needed to
predict each of the other four classes [13]. The 30 probe
sets determined as requirement for accurate class predic-
tion in our study represent 26 genes, a number that could
easily be analyzed in a routine qRT-PCR test. Remarkably,
only eight of these 26 genes were listed among the top 5
subgroup-defining probe sets of the study published by
Ross et al [14]. It is foreseeable that further optimization
towards developing a generic and robust classifier will
lead to an even further reduction in the number of dis-
criminators required to predict some subgroups, whileBMC Cancer 2006, 6:229 http://www.biomedcentral.com/1471-2407/6/229
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additional discriminators may be needed to detect distinct
subtypes within the MLL subgroup [16,39]. Furthermore,
the inclusion of additional translocation-specific assays
should enhance the accurate classification of cases
expressing BCR-ABL.
Using our RMA/RF approach, RF discriminant analysis for
the six ALL subgroups using 120 probe sets achieved very
high average prediction accuracies of 98.2%. These accu-
racies were slightly higher than the previously reported
average prediction accuracy of 94.6% [14], which
included misclassification of cases with more than 50
chromosomes and TEL-AML1  rearrangements. In con-
trast, our analysis classified these specimens with virtually
100% accuracy. TEL-AML1 rearrangements and a hyper-
diploid karyotype with more than 50 chromosomes rep-
resent two of the most frequent genetic abnormalities,
found in 22% and 25%, respectively, of children diag-
nosed with ALL [3]. Given their prognostic significance,
the correct identification of these two subgroups is of great
importance. The presence of either of these features in
paediatric ALL is significantly associated with a favourable
prognosis [9,40-43]. Importantly, because the TEL-AML1
translocation is undetectable by conventional cytogenetic
analysis, more sophisticated molecular techniques, such
as FISH are required to confirm the presence of this fusion
gene [6,7]. Hence, our results further emphasize the
advantage of using gene expression profiles to determine
this prognostically important ALL subgroup.
Conclusion
In summary, we have demonstrated that microarray find-
ings from one study can be confirmed in an independent
study, using an entirely independent patient cohort and
with microarray experiments being performed by a differ-
ent research team. In this study we have excluded discrep-
ancies due to different microarray platforms and our
results argue against recent criticism that gene expression
profiling may not be robust enough to be useful for clini-
cal application [44,45]. The future challenge towards bet-
ter risk stratification includes the refinement of prognostic
marker genes that are associated with outcome. Our find-
ing that only 26 genes are needed for the classification of
six ALL subtypes supports the feasibility of qRT-PCR tech-
nology for standardized diagnostic testing in paediatric
ALL and should, in conjunction with conventional
cytogenetics lead to a more accurate classification of the
disease.
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